このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Improving Delivery of Aging-Related Supportive Care for Older Adults With Acute Myeloid Leukemia (ACTIVE DEFAULT)

2026年8月19日 更新者:Aditi Sharma、University of Alabama at Birmingham

Active Default Pilot: Implementation of Geriatric Assessment-Driven Supportive Care for Older Adults With Acute Myeloid Leukemia Receiving Venetoclax-Based Therapy

The goal of this clinical trial is to test a way of delivering supportive care to adults 60 years and older who are starting venetoclax-based treatment for newly diagnosed acute myeloid leukemia (AML). Older adults with AML often have aging-related needs, such as problems with mobility, nutrition, mood, memory, or medications, that are not always addressed in a consistent way. In this study, a health questionnaire and short in-person checks (a geriatric assessment) are used to find these needs early, and matching supportive care orders are prepared in the electronic health record and sent to the treating doctor, who decides whether to place each one. This approach is called Active Default. The main questions the study aims to answer are:

  • How often are the prepared supportive care orders signed by treating doctors (implementation fidelity)?
  • Can each step of the process, from completing the assessment to receiving supportive care services, be carried out as planned?

Participants will:

  • Complete questionnaires and short in-person checks of walking, balance, strength, memory, mood, and medications at the start of treatment
  • Receive supportive care services (for example physical therapy, nutrition, or social work) if their doctor approves the prepared orders
  • Answer phone check-ins over 90 days and repeat two short checks at about two months
  • Be invited to one optional interview about their experience

Healthcare providers involved in participants' care will be invited to complete a one-time survey and an optional interview about the approach.

調査の概要

状態

まだ募集していません

研究の種類

介入

入学 (推定)

40

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Aditi Sharma, MD
  • 電話番号:205-975-0412
  • メール:adshar@uabmc.edu

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、35233
        • University of Alabama at Birmingham
        • 副調査官:
          • Nicole Henderson, PhD
        • コンタクト:
        • 主任研究者:
          • Aditi Sharma, MD
        • 副調査官:
          • Gabrielle Rocque, MD, MSPH
        • 副調査官:
          • Smita Bhatia, MD, MPH
        • 副調査官:
          • Pankit Vachhani, MD
        • 副調査官:
          • Andres Azuero, PhD, MBA

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

はい

説明

Inclusion Criteria:

Patient participants:

  • Age 60 years or older
  • Newly diagnosed acute myeloid leukemia (AML), including de novo, secondary, or therapy-related AML, per current World Health Organization (WHO) or International Consensus Classification (ICC) classification
  • Planned for first-line venetoclax-based lower-intensity therapy
  • English-speaking
  • Able to provide informed consent personally or through a Legally Authorized Representative (LAR)

Provider participants:

-Participating leukemia attending physicians and supportive care service leads involved in the care of enrolled participants

Exclusion Criteria:

Patient participants:

  • Acute promyelocytic leukemia
  • Planned intensive induction or non-venetoclax-based therapy
  • Life expectancy under 14 days or hospice enrollment at screening

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:ヘルスサービス研究
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Active Default
Patients aged 60 and older with newly diagnosed AML starting venetoclax-based therapy (n=25) receive the Active Default intervention: a geriatric assessment at the start of treatment, with results crossing pre-specified thresholds generating matched supportive care orders that are prepared in the electronic health record and sent to the treating physician to approve or decline. Patients are followed for 90 days, with phone check-ins and repeat physical function and cognition checks at about 60 days. Healthcare providers involved in enrolled patients' care (up to 15) complete a one-time survey and are invited to an optional interview about the approach.
An electronic health record-based order-queuing mechanism that delivers geriatric assessment-driven supportive care. A structured geriatric assessment is completed at the start of venetoclax-based therapy. Results crossing pre-specified thresholds trigger matched supportive care orders (for example physical therapy, nutrition, social work, pharmacy medication review, geriatrics, mental health, chaplaincy), which the study team prepares as proposed orders for the treating physician to approve or decline. The supportive care services themselves are standard of care; the intervention modifies only the order-entry workflow.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Proportion of eligible triggered supportive care orders signed by the treating physician within 7 days (implementation fidelity)
時間枠:Within 7 days of each supportive care order placement; orders are placed after the baseline geriatric assessment and within 7 days before or after Cycle 1 Day 1 of venetoclax-based therapy (each cycle is 28 days)
Measured as the number of eligible geriatric assessment-triggered supportive care orders signed by the treating physician within 7 days of order placement, divided by the total number of eligible triggered orders, using electronic health record order data. Eligible triggers are those not already engaged in the corresponding service or pre-declined by the patient at the pre-referral screen. Reported as a point estimate with 95% Clopper-Pearson confidence interval.
Within 7 days of each supportive care order placement; orders are placed after the baseline geriatric assessment and within 7 days before or after Cycle 1 Day 1 of venetoclax-based therapy (each cycle is 28 days)

二次結果の測定

結果測定
メジャーの説明
時間枠
Proportion of signed supportive care orders with at least one completed service visit (service engagement)
時間枠:90 days from Cycle 1 Day 1, the first day of venetoclax-based therapy (each cycle is 28 days)
Measured as the number of signed supportive care orders with at least one completed visit in the corresponding service within 90 days of Cycle 1 Day 1, divided by the total number of signed orders, using electronic health record data. Reported as a point estimate with 95% Clopper-Pearson confidence interval.
90 days from Cycle 1 Day 1, the first day of venetoclax-based therapy (each cycle is 28 days)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Aditi Sharma, MD、University of Alabama at Birmingham

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年10月1日

一次修了 (推定)

2028年7月31日

研究の完了 (推定)

2028年9月30日

試験登録日

最初に提出

2026年8月17日

QC基準を満たした最初の提出物

2026年8月17日

最初の投稿 (実際)

2026年8月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年8月21日

QC基準を満たした最後の更新が送信されました

2026年8月19日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • IRB-300016966
  • UAB (その他の識別子:UAB)

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する